ROIVANT SCIENCES LTD. Net Income (Loss) Attributable to Noncontrolling Interest
ROIVANT SCIENCES LTD. (ROIV) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$100.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-06
- ROIVANT SCIENCES LTD. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$100.77M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was $52.75M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$47.81M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$52.52M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to noncontrolling interest for fiscal 2026 was -$98.14M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$184.75M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$117.72M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$106.43M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$100.77M 10-Q · filed 2026-08-06 | -$48.02M derived: sum of 2 quarters · filed 2026-08-06 | -$95.83M derived: sum of 3 quarters · filed 2026-08-06 | -$148.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $52.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $4.94M derived: sum of 2 quarters · filed 2026-05-20 | -$47.58M derived: sum of 3 quarters · filed 2026-05-20 | -$98.14M 10-K · filed 2026-05-20 |
| 2025-12-31 | -$47.81M 10-Q · filed 2026-02-06 | -$100.33M derived: sum of 2 quarters · filed 2026-02-06 | -$150.89M 10-Q · filed 2026-02-06 | -$196.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | -$52.52M 10-Q · filed 2025-11-10 | -$103.08M 10-Q · filed 2025-11-10 | -$148.98M derived: sum of 3 quarters · filed 2026-08-06 | -$200.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$50.56M 10-Q · filed 2026-08-06 | -$96.46M derived: sum of 2 quarters · filed 2026-08-06 | -$147.76M derived: sum of 3 quarters · filed 2026-08-06 | -$197.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$45.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$97.21M derived: sum of 2 quarters · filed 2026-05-20 | -$146.95M derived: sum of 3 quarters · filed 2026-05-20 | -$184.75M 10-K · filed 2026-05-20 |
| 2024-12-31 | -$51.31M 10-Q · filed 2026-02-06 | -$101.05M derived: sum of 2 quarters · filed 2026-02-06 | -$138.85M 10-Q · filed 2026-02-06 | -$170.23M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | -$49.74M 10-Q · filed 2025-11-10 | -$87.55M 10-Q · filed 2025-11-10 | -$118.93M derived: sum of 3 quarters · filed 2026-05-20 | -$142.45M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$37.81M 10-Q · filed 2025-08-11 | -$69.19M derived: sum of 2 quarters · filed 2026-05-20 | -$92.71M derived: sum of 3 quarters · filed 2026-05-20 | -$119.50M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | -$31.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$54.90M derived: sum of 2 quarters · filed 2026-05-20 | -$81.69M derived: sum of 3 quarters · filed 2026-05-20 | -$117.72M 10-K · filed 2026-05-20 |
| 2023-12-31 | -$23.52M 10-Q · filed 2025-02-10 | -$50.31M derived: sum of 2 quarters · filed 2025-02-10 | -$86.34M 10-Q · filed 2025-02-10 | -$113.58M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | -$26.79M 10-Q · filed 2024-11-12 | -$62.82M 10-Q · filed 2024-11-12 | -$90.06M derived: sum of 3 quarters · filed 2025-05-29 | -$122.95M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | -$36.03M 10-Q · filed 2024-08-09 | -$63.27M derived: sum of 2 quarters · filed 2025-05-29 | -$96.16M derived: sum of 3 quarters · filed 2025-05-29 | -$120.49M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | -$27.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | -$60.13M derived: sum of 2 quarters · filed 2025-05-29 | -$84.46M derived: sum of 3 quarters · filed 2025-05-29 | -$106.43M 10-K · filed 2025-05-29 |
| 2022-12-31 | -$32.88M 10-Q · filed 2024-02-13 | -$57.21M derived: sum of 2 quarters · filed 2024-02-13 | -$79.19M 10-Q · filed 2024-02-13 | -$100.44M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$24.33M 10-Q · filed 2023-11-13 | -$46.31M 10-Q · filed 2023-11-13 | -$67.56M derived: sum of 3 quarters · filed 2023-11-13 | -$89.11M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$21.98M 10-Q · filed 2023-08-14 | -$43.23M derived: sum of 2 quarters · filed 2023-08-14 | -$64.78M derived: sum of 3 quarters · filed 2023-08-14 | -$81.93M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$21.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$42.80M derived: sum of 2 quarters · filed 2023-06-28 | -$59.96M derived: sum of 3 quarters · filed 2023-06-28 | -$78.85M 10-K · filed 2023-06-28 |
| 2021-12-31 | -$21.55M 10-Q · filed 2023-02-13 | -$38.71M derived: sum of 2 quarters · filed 2023-02-13 | -$57.60M 10-Q · filed 2023-02-13 | -$111.20M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | -$17.16M 10-Q · filed 2022-11-14 | -$36.05M 10-Q · filed 2022-11-14 | -$89.65M derived: sum of 3 quarters · filed 2022-11-14 | -$104.22M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$18.89M 10-Q · filed 2022-08-15 | -$72.49M derived: sum of 2 quarters · filed 2022-08-15 | -$87.06M derived: sum of 3 quarters · filed 2022-08-15 | -$105.16M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$53.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | -$68.17M derived: sum of 2 quarters · filed 2022-06-28 | -$86.27M derived: sum of 3 quarters · filed 2022-06-28 | -$91.00M 10-K · filed 2022-06-28 |
| 2020-12-31 | -$14.57M 10-Q · filed 2022-02-14 | -$32.67M derived: sum of 2 quarters · filed 2022-02-14 | -$37.40M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | -$18.10M 10-Q · filed 2021-11-15 | -$22.83M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$4.73M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |